Bronchospasm medical therapy: Difference between revisions
Jump to navigation
Jump to search
Kiran Singh (talk | contribs) |
|||
Line 28: | Line 28: | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Intensive care medicine]] | [[Category:Intensive care medicine]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 13:15, 2 June 2015
Bronchospasm Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Bronchospasm medical therapy On the Web |
American Roentgen Ray Society Images of Bronchospasm medical therapy |
Risk calculators and risk factors for Bronchospasm medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
Beta 2 Agonists
Beta 2 adrenergic agonists are recommended for bronchospasm.
- Short acting (SABA)
- Long acting (LABA)
- Others
Muscarinic Acetylcholine Receptor Antagonist
Since the neurotransmitter, acetylcholine, is known to decrease sympathetic response by slowing the heart rate and constricting the smooth muscle tissue; ongoing research and successful clinical trials have shown that agents such as diphenhydramine, atropine and Ipratropium bromide are known to be effective for treating asthma and COPD-related symptoms.